SRZN

Surrozen, Inc. (SRZN) - Q1 2026 Filing Summary

Business Context and Reporting Period

This summary covers the Unaudited Condensed Consolidated Financial Statements for Surrozen, Inc. for the quarterly period ended March 31, 2026. Surrozen is a biotechnology company focused on discovering and developing product candidates to selectively modulate the Wnt pathway, with a strategic focus on ophthalmology. The company operates as a single segment and is classified as a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Increase: Total revenue increased by $4.0 million (409%) primarily due to a $5.0 million non-refundable milestone payment from Boehringer Ingelheim for the achievement of a research milestone regarding SZN-413. This offset the cessation of related-party research service revenue ($1.0 million in Q1 2025) following the termination of the TCGFB collaboration.
• Net Loss Expansion: Net loss increased significantly by $100.5 million. This was driven by non-cash charges, specifically a $76.9 million loss on the change in fair value of the tranche liability and a $41.1 million loss on the change in fair value of warrant liabilities. These were partially offset by the absence of the $71.1 million loss on the execution of the 2025 PIPE recorded in the prior year.
• Operating Expenses: Total operating expenses rose 47% to $15.5 million. Research and Development (R&D) expenses increased 42% to $9.3 million due to higher manufacturing and lab costs for SZN-8141. General and Administrative (G&A) expenses increased 54% to $6.1 million, driven by higher employee-related and professional service fees.
• Balance Sheet: Total liabilities increased to $398.9 million from $286.5 million, largely due to the revaluation of the tranche liability ($235.5 million) and warrant liabilities ($148.9 million). Stockholders' deficit widened to $(278.1) million.

Guidance, Outlook, and Risks

• Liquidity: Management believes existing cash of $106.9 million is sufficient to fund operations for at least the next 12 months. However, the company anticipates needing additional capital to execute its long-range business plan.
• Capital Raising: The company sold 1.4 million shares under its At-The-Market (ATM) program for net proceeds of $26.9 million in Q1 2026. The 2025 ATM was terminated in March 2026 and replaced with a new 2026 ATM agreement for up to $50.0 million.
• 2025 PIPE Tranche 2: A second tranche of the 2025 Private Placement, contingent on FDA clearance of the IND for SZN-8141 by October 31, 2026, could provide an additional $95.1 million in gross proceeds.
• Risks: Key risks include the high cost of clinical development, the uncertainty of regulatory approval, the potential for significant dilution from future equity issuances, and the volatility of fair value measurements for tranche and warrant liabilities which heavily impact reported net loss.

Investor Verification Checklist

• Milestone Payment Timing: Verify the receipt of the $5.0 million Boehringer Ingelheim milestone payment (recognized in Q1 2026, received in April 2026) and its impact on cash flow in the subsequent quarter.
• Tranche Liability Valuation: Review the assumptions used to value the $235.5 million tranche liability, as changes in stock price and milestone probabilities significantly drive non-cash losses.
• 2025 PIPE Milestone: Monitor the status of the SZN-8141 IND application, as the October 31, 2026 deadline is critical for unlocking the second tranche of funding.
• ATM Utilization: Track the utilization of the new 2026 ATM program to assess ongoing dilution and cash runway extension.
• Product Pipeline Progress: Confirm preclinical data and IND submission timelines for lead candidates SZN-8141 and SZN-8143 to validate the company's path to clinical trials.